Recent research suggests that the effectiveness and side-effect profile of popular weight-loss medications, such as Ozempic and Zepbound, may be significantly influenced by an individual’s genetic makeup.
A study conducted by the genetic testing company 23andMe, involving over 27,000 users, has identified specific genetic variants that correlate with both greater weight loss and an increased likelihood of gastrointestinal side effects.
The Role of the GLP1R Gene in Weight Loss
The study, published in Nature, focuses on the GLP1R gene, which encodes the receptor that GLP-1 drugs are designed to mimic. These drugs work by simulating a hormone that regulates blood sugar and appetite; by targeting these receptors, they signal the body to feel full.
Researchers discovered that individuals carrying specific variants of the GLP1R gene experience more pronounced results:
– One copy of the variant: Patients lost approximately 0.76 kg (1.7 lbs) more over eight months compared to those without it.
– Two copies of the variant: Patients lost about 1.5 kg (3.3 lbs) more than those without the variant.
While this genetic factor accounts for roughly 10% of the variance in weight loss, experts note its biological significance. Adam Auton, Vice President of Human Genetics at the 23andMe Research Institute, explains that this variant may increase the number of receptor proteins on cell surfaces, providing the medication with more “targets” to act upon.
Predicting Side Effects: A Double-Edged Sword
The same genetic markers that boost weight loss also appear to heighten the risk of common side effects, specifically nausea and vomiting.
While side effects are often viewed negatively, Auton suggests they may serve as a biological indicator of the drug’s efficacy. In many cases, the presence of nausea acts as a “signature” that the medication is actively interacting with the body’s metabolic pathways.
The research also highlighted differences based on the specific type of medication used:
– Semaglutide (Wegovy, Ozempic): Primarily targets GLP-1 receptors.
– Tirzepatide (Zepbound): A dual-action drug that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.
For those taking tirzepatide, a variant in the GIPR gene was found to increase the likelihood of nausea, though it did not significantly impact weight loss. Most notably, patients carrying variants in both the GLP1R and GIPR genes faced 15 times higher odds of vomiting when using tirzepatide.
Why This Matters for the Future of Medicine
This research marks a step toward precision medicine in the field of metabolic health. Currently, weight-loss drugs are often prescribed using a “one size fits all” approach, but these findings suggest that genetic profiling could eventually allow doctors to:
1. Tailor prescriptions: Matching specific drugs to a patient’s genetic profile to maximize weight loss.
2. Manage expectations: Helping patients prepare for the intensity of potential side effects.
3. Improve adherence: Reducing the likelihood of patients discontinuing treatment due to unexpected or severe nausea.
“Genetics alone doesn’t determine how well the drugs will work,” notes Adam Auton, “but knowing which variants a person carries can be quite informative… It may help them prepare themselves for the type of experience they may have.”
Conclusion
While genetics are not the sole determinant of weight loss success, identifying specific GLP1R and GIPR variants provides a roadmap for predicting how patients will respond to GLP-1 medications. This insight paves the way for more personalized and predictable treatments in obesity management.
